Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma

被引:17
作者
Mihailovic, Jasna [1 ,2 ,3 ]
Stefanovic, Ljubomir [1 ,2 ]
Stankovic, Ranka [4 ]
机构
[1] Oncol Inst Vojvodina, Inst Ski Put 4, Dept Nucl Med, Sremska Kamenica 21204, Serbia
[2] Univ Novi Sad, Tech Fac Mihajlo Pupin, Zrenjanin, Serbia
[3] Oncol Inst Vojvodina, Dept Nucl Med, Sremska Kamenica 21204, Serbia
[4] Univ Belgrade, Fac Min & Geol, Belgrade, Serbia
关键词
thyroid gland; microcarcinoma; recurrence; survival; surgery; radioiodine ablation; LYMPH-NODE METASTASIS; PAPILLARY MICROCARCINOMA; RADIOACTIVE IODINE; CARCINOMA; CANCER; EXPERIENCE; ABLATION; THERAPY; PERIOD;
D O I
10.1097/RLU.0b013e3182872ed2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Differentiated thyroid microcarcinoma (DTM) has a good prognosis and survival, but recurrent disease may appear during follow-up. The aim of this study was to evaluate the influence of initial treatment including surgery and radioactive iodine (I-131) on the survival and recurrence in patients with DTM. Methods: Between January 1979 and December 2006, 130 patients with DTM were retrospectively evaluated, with a median follow-up of 10 years. Total/near-total thyroidectomy was performed in 121 (93.1%) of 130 patients, followed with 131I ablation in 71 (54.6%) of 130 patients. Results: The probability of disease-specific survival was 97.7% + 1.3% after 5 and 10 years; the probability of disease-specific survival was 95.9% + 2.2% after 15, 20, 25, and 28 years after the initial treatment and was significantly influenced by recurrence, clinical stage, and patients' age (P = 0.0001, P = 0.0005, and P = 0.02, respectively). Sex, histopathological type of the tumor, metastases at presentation, initial treatment, performance of radioactive therapy, and risk categories had no influence on survival (P = 0.8, P = 0.6, P = 0.1, P = 0.4, P = 0.5, and P = 0.1, respectively). The overall recurrence rate was 10.8%, (6.9% in lymph nodes, 1.5% in thyroid bed, and 2.3% at distant sites), with a median appearance time of 30 months. Recurrences were significantly influenced by regional metastases at presentation, radioiodine ablation, and initial treatment (P = 0.0002, P = 0.005, and P = 0.003, respectively); there was no relationship based on age, sex, histological type of the tumor, and tumor multifocality. Conclusions: To perform more accurate surveillance for recurrence, total/near-total thyroidectomy followed by radioiodine ablation may be the optimal initial treatment for patients with DTM.
引用
收藏
页码:332 / 338
页数:7
相关论文
共 41 条
[1]  
Baudin E, 1998, CANCER, V83, P553, DOI 10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO
[2]  
2-U
[3]  
BISI H, 1989, CANCER-AM CANCER SOC, V64, P1888, DOI 10.1002/1097-0142(19891101)64:9<1888::AID-CNCR2820640922>3.0.CO
[4]  
2-C
[5]   Papillary microcarcinoma of the thyroid - Prognostic significance of lymph node metastasis and multifocality [J].
Chow, SM ;
Law, SCK ;
Chan, JKC ;
Au, SK ;
Yau, S ;
Lau, WH .
CANCER, 2003, 98 (01) :31-40
[6]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[7]   Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].
Davies, L ;
Welch, HG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167
[8]  
[Deutsche Krebsgesselschaft Deutsche Gesellschaft fur Chirurgie], 2002, DTSCH KREBS DTSCH CH
[9]   Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough? [J].
Dietlein, M ;
Luyken, WA ;
Schicha, H ;
Larena-Avellaneda, A .
NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (01) :3-8
[10]  
Dietlein M, 2007, NUKLEARMEDIZIN, V46, P2